Michael Kauffman, Chief Executive Officer at Karyopharm Therapeutics Inc. (KPTI), sold 26,486 shares at $15.52 ($411K) on 2021-02-11, disclosed to the SEC on 2021-02-17.
Open-market sale of $411k KPTI by Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.52 | 6,601 | $102K | 24.9% |
| 2 | $15.52 | 6,601 | $102K | 24.9% |
| 3 | $15.52 | 6,642 | $103K | 25.1% |
| 4 | $15.52 | 6,642 | $103K | 25.1% |
| Total | $15.52 avg | 26,486 | $411K | 100% |
| Filing → |
| KPTI | SELL | 2022-03-02 | $128K | — | Filing → |
| KPTI | SELL | 2022-02-22 | $440K | — | Filing → |
| KPTI | SELL | 2022-02-09 | $266K | — | Filing → |